Joseph Chao1, Charles S Fuchs2, Kohei Shitara3, Josep Tabernero4, Kei Muro5, Eric Van Cutsem6, Yung-Jue Bang7, Ferdinando De Vita8, Gregory Landers9, Chia-Jui Yen10, Ian Chau11, Anneli Elme12, Jeeyun Lee13, Mustafa Özgüroglu14, Daniel Catenacci15, Harry H Yoon16, Erluo Chen17, David Adelberg17, Chie-Schin Shih17, Sukrut Shah17, Pooja Bhagia17, Zev A Wainberg18. 1. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California. 2. Yale Cancer Center, Smilow Cancer Hospital, New Haven, Connecticut. 3. National Cancer Center Hospital East, Kashiwa, Japan. 4. Vall d'Hebron University Hospital and Institute of Oncology, Baselga Oncological Institute-Quiron, University of Vic-Central University of Catalonia, Barcelona, Spain. 5. Aichi Cancer Center Hospital, Nagoya, Japan. 6. University Hospital Leuven and KU Leuven, Leuven, Belgium. 7. Seoul National University College of Medicine, Seoul, Republic of Korea. 8. University of Study of Campania Luigi Vanvitelli, Naples, Italy. 9. The Oncology Centre, Durban, South Africa. 10. National Cheng Kung University Hospital, Taiwan, People's Republic of China. 11. Royal Marsden Hospital, Sutton, Surrey, United Kingdom. 12. North Estonia Medical Center Foundation, Tallinn, Estonia. 13. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 14. Cerrahpaşa Medical Faculty, Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey. 15. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois. 16. Mayo Clinic, Rochester, Minnesota. 17. Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, New Jersey. 18. David Geffen School of Medicine, University of California, Los Angeles.
Abstract
IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab therapy vs chemotherapy among patients with MSI-H advanced gastric or gastroesophageal junction (G/GEJ) cancer regardless of the line of therapy in which it was received. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the phase 2 KEYNOTE-059 (third-line treatment or higher) single-arm trial and the phase 3 KEYNOTE-061 (second-line treatment) and KEYNOTE-062 (first-line treatment) randomized trials included patients with advanced G/GEJ cancer from 52 sites in 16 countries enrolled in KEYNOTE-059, 148 sites in 30 countries enrolled in KEYNOTE-061, and 200 sites in 29 countries enrolled in KEYNOTE-062. Patients were enrolled from March 2, 2015, to March 26, 2016, in KEYNOTE-059; from June 4, 2015, to July 26, 2016, in KEYNOTE-061; and from September 18, 2015, to May 26, 2017, in KEYNOTE-062, with data cutoff dates of August 8, 2018; October 26, 2017; and March 26, 2019; respectively. INTERVENTIONS: Pembrolizumab monotherapy in KEYNOTE-059, pembrolizumab monotherapy or chemotherapy (paclitaxel) in KEYNOTE-061, and pembrolizumab monotherapy, pembrolizumab plus chemotherapy (cisplatin and 5-fluorouracil or capecitabine), or chemotherapy alone in KEYNOTE-062. MAIN OUTCOMES AND MEASURES: Response was assessed centrally using Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1; MSI-H status was determined centrally by polymerase chain reaction testing. RESULTS: At data cutoff, 7 of 174 patients (4.0%) in KEYNOTE-059, 27 of 514 patients (5.3%) in KEYNOTE-061, and 50 of 682 patients (7.3%) in KEYNOTE-062 had MSI-H tumors. Among those with MSI-H tumors, the median overall survival was not reached (NR) for pembrolizumab in KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 or for pembrolizumab plus chemotherapy in KEYNOTE-062. The median progression-free survival (PFS) for pembrolizumab was NR (95% CI, 1.1 months to NR) in KEYNOTE-059 and 17.8 months (95% CI, 2.7 months to NR) in KEYNOTE-061 (vs 3.5 months [95% CI, 2.0-9.8 months] for chemotherapy). In KEYNOTE-062, the median PFS was 11.2 months (95% CI, 1.5 months to NR) for pembrolizumab, NR (95% CI, 3.6 months to NR) for pembrolizumab plus chemotherapy, and 6.6 months (95% CI, 4.4-8.3 months) for chemotherapy. The objective response rate (ORR) for pembrolizumab was 57.1% in KEYNOTE-059 and 46.7% (vs 16.7% for chemotherapy) in KEYNOTE-061. In KEYNOTE-062, the ORR was 57.1% for pembrolizumab , 64.7% for pembrolizumab plus chemotherapy, and 36.8% for chemotherapy. CONCLUSIONS AND RELEVANCE: Findings from this study indicate that MSI-H status may be a biomarker for pembrolizumab therapy among patients with advanced G/GEJ cancer regardless of the line of therapy in which it was received. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02335411, NCT02370498, and NCT02494583.
IMPORTANCE: Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors. OBJECTIVE: To evaluate the antitumor activity of pembrolizumab therapy vs chemotherapy among patients with MSI-H advanced gastric or gastroesophageal junction (G/GEJ) cancer regardless of the line of therapy in which it was received. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the phase 2 KEYNOTE-059 (third-line treatment or higher) single-arm trial and the phase 3 KEYNOTE-061 (second-line treatment) and KEYNOTE-062 (first-line treatment) randomized trials included patients with advanced G/GEJ cancer from 52 sites in 16 countries enrolled in KEYNOTE-059, 148 sites in 30 countries enrolled in KEYNOTE-061, and 200 sites in 29 countries enrolled in KEYNOTE-062. Patients were enrolled from March 2, 2015, to March 26, 2016, in KEYNOTE-059; from June 4, 2015, to July 26, 2016, in KEYNOTE-061; and from September 18, 2015, to May 26, 2017, in KEYNOTE-062, with data cutoff dates of August 8, 2018; October 26, 2017; and March 26, 2019; respectively. INTERVENTIONS: Pembrolizumab monotherapy in KEYNOTE-059, pembrolizumab monotherapy or chemotherapy (paclitaxel) in KEYNOTE-061, and pembrolizumab monotherapy, pembrolizumab plus chemotherapy (cisplatin and 5-fluorouracil or capecitabine), or chemotherapy alone in KEYNOTE-062. MAIN OUTCOMES AND MEASURES: Response was assessed centrally using Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1; MSI-H status was determined centrally by polymerase chain reaction testing. RESULTS: At data cutoff, 7 of 174 patients (4.0%) in KEYNOTE-059, 27 of 514 patients (5.3%) in KEYNOTE-061, and 50 of 682 patients (7.3%) in KEYNOTE-062 had MSI-H tumors. Among those with MSI-H tumors, the median overall survival was not reached (NR) for pembrolizumab in KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 or for pembrolizumab plus chemotherapy in KEYNOTE-062. The median progression-free survival (PFS) for pembrolizumab was NR (95% CI, 1.1 months to NR) in KEYNOTE-059 and 17.8 months (95% CI, 2.7 months to NR) in KEYNOTE-061 (vs 3.5 months [95% CI, 2.0-9.8 months] for chemotherapy). In KEYNOTE-062, the median PFS was 11.2 months (95% CI, 1.5 months to NR) for pembrolizumab, NR (95% CI, 3.6 months to NR) for pembrolizumab plus chemotherapy, and 6.6 months (95% CI, 4.4-8.3 months) for chemotherapy. The objective response rate (ORR) for pembrolizumab was 57.1% in KEYNOTE-059 and 46.7% (vs 16.7% for chemotherapy) in KEYNOTE-061. In KEYNOTE-062, the ORR was 57.1% for pembrolizumab , 64.7% for pembrolizumab plus chemotherapy, and 36.8% for chemotherapy. CONCLUSIONS AND RELEVANCE: Findings from this study indicate that MSI-H status may be a biomarker for pembrolizumab therapy among patients with advanced G/GEJ cancer regardless of the line of therapy in which it was received. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02335411, NCT02370498, and NCT02494583.
Authors: Kohei Shitara; Mustafa Özgüroğlu; Yung-Jue Bang; Maria Di Bartolomeo; Mario Mandalà; Min-Hee Ryu; Lorenzo Fornaro; Tomasz Olesiński; Christian Caglevic; Hyun C Chung; Kei Muro; Eray Goekkurt; Wasat Mansoor; Raymond S McDermott; Einat Shacham-Shmueli; Xinqun Chen; Carlos Mayo; S Peter Kang; Atsushi Ohtsu; Charles S Fuchs Journal: Lancet Date: 2018-06-04 Impact factor: 79.321
Authors: Yelena Y Janjigian; Francisco Sanchez-Vega; Philip Jonsson; Walid K Chatila; Jaclyn F Hechtman; Geoffrey Y Ku; Jamie C Riches; Yaelle Tuvy; Ritika Kundra; Nancy Bouvier; Efsevia Vakiani; Jianjiong Gao; Zachary J Heins; Benjamin E Gross; David P Kelsen; Liying Zhang; Vivian E Strong; Mark Schattner; Hans Gerdes; Daniel G Coit; Manjit Bains; Zsofia K Stadler; Valerie W Rusch; David R Jones; Daniela Molena; Jinru Shia; Mark E Robson; Marinela Capanu; Sumit Middha; Ahmet Zehir; David M Hyman; Maurizio Scaltriti; Marc Ladanyi; Neal Rosen; David H Ilson; Michael F Berger; Laura Tang; Barry S Taylor; David B Solit; Nikolaus Schultz Journal: Cancer Discov Date: 2017-11-09 Impact factor: 39.397
Authors: Aurelien Marabelle; Dung T Le; Paolo A Ascierto; Anna Maria Di Giacomo; Ana De Jesus-Acosta; Jean-Pierre Delord; Ravit Geva; Maya Gottfried; Nicolas Penel; Aaron R Hansen; Sarina A Piha-Paul; Toshihiko Doi; Bo Gao; Hyun Cheol Chung; Jose Lopez-Martin; Yung-Jue Bang; Ronnie Shapira Frommer; Manisha Shah; Razi Ghori; Andrew K Joe; Scott K Pruitt; Luis A Diaz Journal: J Clin Oncol Date: 2019-11-04 Impact factor: 44.544
Authors: Soo Young Kim; Yoon Young Choi; Ji Yeong An; Hyun Beak Shin; Ara Jo; Hyeji Choi; Sang Hyuk Seo; Hui-Jae Bang; Jae-Ho Cheong; Woo Jin Hyung; Sung Hoon Noh Journal: Int J Cancer Date: 2015-02-26 Impact factor: 7.396
Authors: Charles S Fuchs; Toshihiko Doi; Raymond W Jang; Kei Muro; Taroh Satoh; Manuela Machado; Weijing Sun; Shadia I Jalal; Manish A Shah; Jean-Phillipe Metges; Marcelo Garrido; Talia Golan; Mario Mandala; Zev A Wainberg; Daniel V Catenacci; Atsushi Ohtsu; Kohei Shitara; Ravit Geva; Jonathan Bleeker; Andrew H Ko; Geoffrey Ku; Philip Philip; Peter C Enzinger; Yung-Jue Bang; Diane Levitan; Jiangdian Wang; Minori Rosales; Rita P Dalal; Harry H Yoon Journal: JAMA Oncol Date: 2018-05-10 Impact factor: 31.777
Authors: T Yoshino; G Pentheroudakis; S Mishima; M J Overman; K-H Yeh; E Baba; Y Naito; F Calvo; A Saxena; L-T Chen; M Takeda; A Cervantes; H Taniguchi; K Yoshida; Y Kodera; Y Kitagawa; J Tabernero; H Burris; J-Y Douillard Journal: Ann Oncol Date: 2020-04-06 Impact factor: 32.976
Authors: Dung T Le; Tae Won Kim; Eric Van Cutsem; Ravit Geva; Dirk Jäger; Hiroki Hara; Matthew Burge; Bert O'Neil; Petr Kavan; Takayuki Yoshino; Rosine Guimbaud; Hiroya Taniguchi; Elena Elez; Salah-Eddin Al-Batran; Patrick M Boland; Todd Crocenzi; Chloe E Atreya; Yi Cui; Tong Dai; Patricia Marinello; Luis A Diaz; Thierry André Journal: J Clin Oncol Date: 2019-11-14 Impact factor: 44.544
Authors: Bérengère Salomé; John P Sfakianos; Daniel Ranti; Jorge Daza; Christine Bieber; Andrew Charap; Christian Hammer; Romain Banchereau; Adam M Farkas; Dan Fu Ruan; Sudeh Izadmehr; Daniel Geanon; Geoffrey Kelly; Ronaldo M de Real; Brian Lee; Kristin G Beaumont; Sanjana Shroff; Yuanshuo A Wang; Ying-Chih Wang; Tin Htwe Thin; Monica Garcia-Barros; Everardo Hegewisch-Solloa; Emily M Mace; Li Wang; Timothy O'Donnell; Diego Chowell; Ruben Fernandez-Rodriguez; Mihaela Skobe; Nicole Taylor; Seunghee Kim-Schulze; Robert P Sebra; Doug Palmer; Eleanor Clancy-Thompson; Scott Hammond; Alice O Kamphorst; Karl-Johan Malmberg; Emanuela Marcenaro; Pedro Romero; Rachel Brody; Mathias Viard; Yuko Yuki; Maureen Martin; Mary Carrington; Reza Mehrazin; Peter Wiklund; Ira Mellman; Sanjeev Mariathasan; Jun Zhu; Matthew D Galsky; Nina Bhardwaj; Amir Horowitz Journal: Cancer Cell Date: 2022-09-12 Impact factor: 38.585
Authors: Nicole M Myer; Kohei Shitara; Hyun C Chung; Florian Lordick; Ronan J Kelly; Zsolt Szabo; Z Alexander Cao; Stephen Leong; David H Ilson; Wilko Weichert Journal: J Cancer Res Clin Oncol Date: 2022-05-13 Impact factor: 4.322